Teva

2Q Revenues: $5.0 billion (+19%)

2Q Earnings: $863 million (+50%)

YTD Revenues: $10.1 billion (+22%)

YTD Earnings: $1.7 billion (+27%)

Comments: Revenues in the U.S. in the quarter were $2.5 billion (representing 49% of total revenues), up 28%. Revenues in Europe were flat at $1.5 billion, or 30% of total revenues. Rest of the World (ROW) revenues were $1.1 billion (21% of total revenues), up 30%. Generic revenues were $2.6 billion, up 9%. Branded revenues were $1.9 billion, up 37%, primarily due to the inclusion of Cephalon sales (Treanda with $139 million, and Nuvigil with $91 million). Sales of Provigil dropped to $48 million due to generic competition. OTC revenues were $219 million, up 21%.